GlassScriptPhysician profile
Linda D Moors
NPI 1295776912
$122,378.48
in general payments reported to CMS, 2019-2025
33 companies · $29K in 2025
The $29K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16K · 2022: $14K · 2023: $27K · 2024: $36K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $60K · Travel and Lodging: $21K · Food and Beverage: $6,576 · Consulting Fee: $4,795 · Long Term Medical Supply Or Device Loan: $682 · Education: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $59,998.96 |
| Travel and Lodging | $20,526.90 |
| Food and Beverage | $6,575.97 |
| Consulting Fee | $4,795.00 |
| Long Term Medical Supply Or Device Loan | $681.53 |
| Education | $224.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $81,548.17 | 2021-2025 | Enhertu, Datroway, Lynparza |
| Daiichi Sankyo INC. | $34,866.24 | 2021-2025 | Enhertu, Datroway |
| Hologic Sales and Service, LLC | $1,678.26 | 2023 | Btx, Aptima, Fetal Fibronectin Enzyme Immunoassay |
| Novartis Pharmaceuticals Corporation | $1,175.66 | 2022-2024 | |
| Stemline Therapeutics INC. | $1,091.39 | 2023-2024 | Orserdu |
| Seagen INC. | $291.13 | 2021-2023 | Tukysa |
| Pfizer INC. | $261.31 | 2024 | |
| Sumitomo Pharma America, INC. | $176.80 | 2023-2024 | Orgovyx |
| Abbvie INC. | $163.91 | 2025 | |
| Glaxosmithkline, LLC. | $121.49 | 2023 | Ojjaara |
| Pharmacyclics LLC, An Abbvie Company | $115.41 | 2021 | |
| Incyte Corporation | $107.58 | 2022-2025 | Jakafi, Zynyz, Monjuvi |
| Gilead Sciences, INC. | $100.92 | 2021-2023 | Trodelvy |
| Sanofi-Aventis U.S. LLC | $96.00 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $90.57 | 2024 | Onivyde |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $65.67 | 2023 | Monoferric |
| Myovant Sciences INC. | $51.51 | 2021 | |
| Janssen Biotech, INC. | $39.62 | 2024 | Akeega, Erleada, Carvykti |
| Legend Biotech USA INC. | $35.52 | 2024 | |
| Genentech USA, INC. | $34.15 | 2024 | Columvi, Lunsumio, Polivy |
| E.R. Squibb & Sons, L.L.C. | $28.69 | 2022-2023 | Opdivo |
| Dendreon Pharmaceuticals LLC | $24.99 | 2024 | Provenge |
| Caris Mpi, INC. | $24.33 | 2025 | Mi Cancer Seek |
| Tersera Therapeutics LLC | $23.92 | 2023 | Zoladex |
| Eisai INC. | $23.24 | 2024 | |
| Amneal Pharmaceuticals LLC | $22.37 | 2024 | Neulasta, Neupogen, Avastin |
| Genzyme Corporation | $22.01 | 2023 | |
| Immunocore Limited | $19.90 | 2024 | Kimmtrak |
| Agios Pharmaceuticals, INC. | $19.57 | 2024 | Pyrukynd |
| Astellas Pharma US INC | $16.89 | 2023 | Xtandi |
| Celgene Corporation | $16.15 | 2023 | Reblozyl |
| Mirati Therapeutics, INC. | $13.34 | 2023 | Krazati |
| Merck Sharp & Dohme LLC | $11.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linda Moors listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.